Grace Therapeutics, Inc（GRCE）财务数据GRCEGrace Therapeutics, Inc

Evaluating the bottom line, Grace Therapeutics, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -36.19%, provide a clear picture of how effectively GRCE converts its operational activities into shareholder value.

In the context of the broader market, GRCE competes directly with industry leaders such as VERU and MGX. With a market capitalization of $45.44M, it holds a significant position in the sector. When comparing efficiency, GRCE's gross margin of N/A stands against VERU's N/A and MGX's 100.00%. Such benchmarking helps identify whether Grace Therapeutics, Inc is trading at a premium or discount relative to its financial performance.

Grace Therapeutics reported a net loss of $7.8 million for FY 2026, translating to a loss of $0.47 per share, which is an improvement from the $9.6 million loss in the previous year, indicating some financial management improvements.